<DOC>
	<DOC>NCT00382837</DOC>
	<brief_summary>Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments</brief_summary>
	<brief_title>Study of Epratuzumab in Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Must have completed SL0003 Alleviate A through 48 weeks Development of toxicity to Epratuzumab Significant protocol deviations from SL0003 Study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Lupus,</keyword>
	<keyword>Antibody,</keyword>
	<keyword>B-Cell immunotherapy</keyword>
</DOC>